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Objective: To evaluate the ability of serum anti-Müllerian hormone (AMH), FSH, and age to clinically predict ovarian response to controlled ovar-
ian hyperstimulation (COH) in IVF patients with endometriosis.
Methods: We evaluated 91 COH cycles, including 43 cycles with endometriosis (group I) and 48 cycles with male factor infertility (group II) from 
January to December, 2010. Patients were classified into study groups based on their surgical history of endometriosis-group Ia (without surgi-
cal history, n=16), group Ib (with a surgical history, n=27). 
Results: The mean age was not significantly different between group I and group II. However, AMH and FSH were significantly different be-
tween group I and group II (1.9±1.9 ng/mL vs. 4.1±2.9 ng/mL, p<0.01; 13.1±7.2 mIU/mL vs. 8.6±3.3 mIU/mL, p<0.01). Furthermore, the 
number of retrieved oocytes and the number of matured oocytes were significantly lower in group I than in group II. In group II, AMH and FSH 
as well as age were significant predictors of retrieved oocytes on univariate analysis. Only the serum AMH level was a significant predictor of 
poor ovarian response in women with endometriosis. 
Conclusion: Serum AMH may be a better predictor of the ovarian response of COH in patients with endometriosis than basal FSH or age. AMH 
level can be considered a useful clinical predictor of poor ovarian response in endometriosis patients. 
Keywords: Anti-Müllerian hormone (Müllerian inhibiting substance); Ovarian stimulation; Endometriosis; In vitro fertilization; Intracytoplasmic 
sperm injection; Human
Introduction
Endometriosis is defined as the presence of endometrial-like tissue 
(glands and stroma) outside the uterus, which induces a chronic in-
flammatory reaction, scar tissue, and adhesions [1]. It is a frequent 
gynecological disorder that occurs in 6-10% of the female population 
and is more frequent in infertile women, where it occurs in 25-40% 
[2,3]. 
Women with endometriosis have a lower ovarian reserve and high 
basal FSH level than women of the same age who do not have endo-
metriosis [4,5]. However, unlike women with a diminished ovarian 
reserve due to advanced reproductive age or incipient premature 
ovarian failure, women with endometriosis do not exhibit poor em-
bryo quality or a reduced implantation rate [6]. Thus, assessment of 
ovarian reserve in women with endometriosis undergoing controlled 
ovarian hyperstimulation (COH) has been an important problem. 
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Many studies suggest that markers for ovarian reserve may behave 
differently in women with and without endometriosis [7,8]. However, 
there are few studies to identify markers of ovarian reserve and pre-
dict the response to COH in women with endometriosis. 
Recently, anti-Müllerian hormone (AMH) has emerged as a novel 
marker for ovarian reserve [9-11]. AMH is expressed in the growing 
preantral or small antral follicles in the ovary [12] and reflects the re-
cruited ovarian follicular pool [10]. Serum AMH levels decrease steadi-
ly with increasing age and are undetectable after menopause [13,14]. 
In assisted reproductive technology, serum AMH levels accurately re-
flect the total developing follicular cohort and predict the ovarian re-
sponse to COH [15-17].
Several investigators demonstrated lower basal AMH levels among 
women with endometriosis [18]. However, there are few studies for 
correlation between serum AMH and ovarian response to COH in wo-
men with endometriosis. Therefore, in this study, we aimed to evalu-
ate the clinical predictability of serum AMH, FSH, and age as predic-
tors of ovarian response to COH in patients with endometriosis. 
Methods
1. Study population
From January 1st, 2010 to December 31st, 2010, 2,163 non-donor, 
fresh IVF cycles performed in Cheil General Hospital and Women’s 
Health Care Center with recorded AMH concentrations were retro-
spectively identified. The inclusion criteria of this study include the 
following factors: 1) infertility associated with endometriosis or male 
factor infertility, 2) age ≤43 years old, 3) body mass index (BMI) <30 
kg/m
2, 4) absence of polycystic ovarian syndrome (PCOS), 5) absence 
of other endocrine disease (thyroid disease, diabetes mellitus, Cush-
ing’s syndrome). Following these criteria, the final study population 
consisted of 43 cycles with endometriosis as the study group (group 
I) and 48 cycles with exclusive male factor infertility as the control 
group (group II). In order to determine any differences according to 
surgery of endometriosis, the study groups were classified according 
to their surgical history-group Ia (without surgical history, n=16), 
group Ib (with surgical history, n=27). Poor ovarian response to COH 
was defined as a number of retrieved oocytes not exceeding three. 
The study was approved by the Institutional Review Board of Cheil 
General Hospital and Women’s Healthcare Center, Kwandong Univer-
sity College of Me dicine.
Serum AMH was drawn within 3 months prior to ovarian stimula-
tion, independent of menstrual cycle day. Assays were performed by 
enzyme immunoassay using an AMH/MIS EIA kit (Immunotech ver-
sion; Beckman Coulter, Marseille, France). On day 2-3 of the sponta-
neous menstrual cycle, the blood samples for the assay of FSH and E2 
were obtained by venipuncture. 
2. Ovarian stimulation protocol
An ovarian hyperstimulation protocol was initiated after confirm-
ing the lack of any growing follicle greater than 10 mm in diameter 
by ultrasound, and basal serum E2 not exceeding 50 pg/mL on day 2 
or 3 of the menstrual cycle. Ovarian hyperstimulation was achieved 
either by short or long protocols using GnRH agonist leuprolide (Lu-
crin, Abott Korea Ltd., Seoul, Korea) or short protocols using 0.25 mg 
GnRH antagonists (Cetrotide; Merck Serno, Geneva, Switzerland or 
Orgalutran; Schering-Plough Organon, Oss, the Netherlands). Recom-
binant hCG (Ovidrel, Merck Serno) was administered subcutaneously 
in a single 250 μg dose when a dominant follicle had reached a maxi-
mum diameter of 18 mm or greater. Follicle aspiration was performed 
approximately 34-36 hours after hCG administration for oocyte re-
trieval.
3. Statistical analysis
Statistical analysis was performed with SPSS ver. 12.0 (SPSS Inc., Chi-
cago, IL, USA). Comparisons of data between groups were performed 
with the Student’s t-test. Each variable is presented as mean±SD. Pear-
son’s correlation and Spearman’s correlation were utilized to analyze 
the correlations between variables. Areas under receiver operating 
characteristic curves were utilized to predict poor ovarian response 
to COH. A p-value of below 0.05 was considered to be statistically sig-
nificant. 
Results
There was no significant difference in age, BMI, number of previous 
IVF cycles, or duration of infertility between the study group (group I) 
and the control group (group II) (Table 1). The serum AMH level was 
significantly lower in group I than group II (1.9±1.9 vs. 4.1±2.9), 
whereas the basal FSH level was significantly higher in group I than 
group II (13.1±7.2 vs. 8.6±3.3) (Figure 1). However, there was no sig-
nificant difference in basal E2 levels. When we analyzed subgroups of 
the study group, there was no significant difference in age (35.7±3.2 
vs. 34.4±4.6), AMH (1.6±1.1 vs. 2.1±2.2), FSH (10.9±4.4 vs. 14.3±8.2), 
the number of retrieved oocytes (5.8±5.3 vs. 6.5±6.9), or the num-
ber of matured oocytes (4.7±4.3 vs. 5.3±5.9) between group Ia and 
group Ib. 
There was no significant difference in the duration of stimulation or 
dosage of gonadotropins between group I and group II. However, the 
number of retrieved oocytes and number of mature oocytes were 
significantly fewer in group I than group II (Table 1). 
The number of retrieved oocytes was more correlated with the se-
rum AMH level than with the serum FSH in both groups (Figures 2, 3). 
A significant negative correlation between age and variables of ovar-
ian response was obtained for both groups. In addition, the serum   http://dx.doi.org/10.5653/cerm.2011.38.4.222
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AMH level was positively and significantly correlated with the num-
ber of retrieved oocytes and number of mature oocytes in both groups. 
However, the serum FSH was not correlated with the number of ma-
ture oocytes in group I (Table 2). In group Ia, only serum AMH was sig-
nificantly correlated with the number of retrieved oocytes (rs=0.703, 
p<0.001), whereas in group Ib, AMH and age had a high correlation 
with the number of retrieved oocytes (rs=0.736, p<0.001, rs=0.640, 
p<0.001). However, in group Ia and group Ib, FSH did not present a 
correlation with the number of retrieved oocytes (rs=-0.209, not sig-
nificant [NS], rs= -0.326, NS). 
We also analyzed the cut-off value of AMH and FSH by using the re-
ceiver operating characteristic curve to predict poor ovarian response 
in both groups (Figure 4). We demonstrated that the serum AMH lev-
el was the most important marker, with a significant ability for deter-
mination of poor ovarian response in the study group (area under 
the curve [AUC]=0.845 [95% confidence interval, CI: 0.727-0.964]), 
with 73.3% sensitivity and 82.1% specificity, for AMH levels ≤0.95 
ng/mL. However, basal FSH was not significant in group I (AUC=0.587 
[95% CI: 0.391-0.782], NS) (Figure 4).
Discussion
Although ART procedures have been successful in infertile women 
with endometriosis, poorer results are still expected for women with 
the disease [7]. Several studies have suggested that follicle and oo-
cyte impairment eventually disrupts the reproductive function of 
women with endometriosis. Therefore, many investigators have at-
tempted to identify markers of ovarian reserve also capable of pre-
dicting response to treatment in these women. 
The current study showed that the serum AMH level showed a sta-
tistically significant positive correlation with the number of retrieved 
oocytes and the number of mature oocytes in both groups. However, 
there was no correlation between serum FSH and number of mature 
oocytes in women with endometriosis. These results indicate that in 
women with endometriosis, regardless of their surgical history, the 
serum AMH level might be a better marker for predicting the num-
ber of oocytes retrieved undergoing COH than serum FSH or age. 
Some studies have presented an association between serum AMH 
Table 1. Clinical characteristics of IVF patients between women with 
endometriosis (group I) and women with male factor (group II)
Group I
(endo metriosis)
Group II
(male factor) p-value
No. of patients 43 48
Age (yr) 34.9±4.2 35.2±4.7 NS
BMI (kg/m²) 20.2±2.0 21.2±3.3 NS
No. of previous IVF cycles 0.6±1.7 0.6±1.8 NS
Duration of infertility (mo) 35.9±22.3 44.9±33.1 NS
Basal FSH (mIU/mL) 13.1±7.2 8.6±3.3 <0.01
AMH (ng/mL)  1.9±1.9 4.1±2.9 <0.01
Mean serum E2 on hCG day 2,001.0±2,184.8 2,778.6±2,721.7 NS
Duration of stimulation (day) 10.0±1.9 10.1±2.0 NS
Dosage of gonadotropins (IU) 2,619±1,152 2,680±1,029 NS
No. of retrieved oocytes 6.3±6.3 13.1±10.4 <0.01
No. of mature oocytes 5.1±5.3 9.5±8.1 <0.01
Fertilization rate (%) 68.8±26.3 62.4±23.0 NS
Implantation rate (%) 16.1±30.5 20.9±31.4 NS
Clinical pregnancy rate (%) 18.6 (8/43) 33.3 (16/48) NS
The values are expressed as mean±SD. 
BMI, body mass index; AMH, anti-Müllerian hormone; NS, not significant.
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Figure 1. Comparison of serum anti-Müllerian hormone (AMH) levels and serum FSH levels of women with endometriosis and women with 
male factor infertility (control).www.eCERM.org
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and ovarian function. Serum AMH decreases steadily with advancing 
age and declining ovarian function, whereas the other serum ovarian 
reserve tests such as FSH and inhibin B utilize cutoff values for nor-
mal ovarian function [11]. Therefore, serum AMH may be useful in 
women with endometriosis who present progressive loss of ovarian 
reserve with advancing disease. With similar results, Knauff et al. [19] 
reported that compared with inhibin B and antral follicle counts, AMH 
was more consistently correlated with the clinical degree of follicle 
pool depletion in young hypergonadotropic patients such as tran-
sient ovarian failure, incipient ovarian failure, and premature ovarian 
failure. That study suggested that AMH indicates a more accurate as-
sessment of the follicle pool in young women presenting with ele-
vated FSH levels. 
In the current study, the serum AMH level was significantly lower in 
the study group when compared with that of the control group. Fur-
thermore, the serum FSH level was significantly higher in the study 
group. Several studies have investigated ovarian reserve in endome-
triosis. Lemos et al. [18] demonstrated that infertile patients with min-
Figure 2. Correlation between the number of retrieved oocytes and serum anti-Müllerian hormone (AMH) level. 
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Figure 3. Correlation between the number of retrieved oocytes and serum FSH level.
A B
40
30
20
10
0
N
o
.
 
o
f
 
r
e
t
r
i
e
v
e
d
 
o
o
c
y
t
e
s
FSH (mIU/mL)
0.0  10.0  20.0  30.0
 Women with male factor
R
2=0.32, p<0.01
40
30
20
10
0
N
o
.
 
o
f
 
r
e
t
r
i
e
v
e
d
 
o
o
c
y
t
e
s
FSH (mIU/mL)
0.0  10.0  20.0  30.0
Women with endometriosis
R
2=0.11, p=0.029  http://dx.doi.org/10.5653/cerm.2011.38.4.222
  Clin Exp Reprod Med 2011;38(4):222-227
226
Table 2. Correlation between the number of retrieved oocytes and serum AMH, FSH, and age in group I and II
Group I (endometriosis) Group II (male factor)
No. of  retrieved oocytes No. of mature oocytes No. of retrieved oocytes No. of mature oocytes
rp p rp p rp p rp p
Age (yr)  -0.471 0.001 -0.412 0.006 -0.477 0.007 -0.452 0.001
AMH (ng/mL) 0.841 <0.001 0.776 <0.001 0.732 <0.001 0.637 <0.001
Basal FSH (mIU/mL) -0.333 0.029 -0.295 NS -0.569 <0.001 -0.535 <0.001
Basal E2 (pg/mL) -0.010 NS -0.084 NS 0.156 NS 0.061 NS
AMH, anti-Müllerian hormone; NS, not significant.
Figure 4. Receiver operating characteristic curves for basal FSH and anti-Müllerian hormone (AMH), as predictors of a poor ovarian response to 
controlled ovarian hyperstimulation (COH) in groups I and II.
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imal or mild endometriosis had decreased serum AMH compared to 
a control group. In that study, the two groups’ serum FSH did not dif-
fer. However, Hock et al. [8] reported a significant increase in basal 
FSH levels in women with advanced endometriosis, supporting the 
idea of a progressive loss of ovarian function as the disease advances. 
Likewise, Falconer et al. [20] reported that women with endometrio-
sis had significantly lower AMH in serum and follicular fluid, and high-
er concentrations of TNF, IL-15, and GM-CSF in the follicular fluid. They 
suggested that women with endometriosis have a reduced repro-
ductive potential because of increased inflammatory activity. These 
results are similar to our findings. In the current study, the number of 
retrieved oocytes and the number of mature oocytes were significant-
ly fewer in the study group than the control group. This suggests that 
endometriosis is associated with the reduction of ovarian reserve and 
poor ovarian response to COH. 
Among the predictors of ovarian response, serum AMH compared 
to FSH had a several advantages such as low intercycle and intracycle 
variability, menstrual cycle-independent [21]. This study demonstrat-
ed that only the serum AMH level was significantly valuable in pre-
dicting a poor ovarian response for women with endometriosis. The 
cut-off value of serum AMH for poor response will be helpful deter-
mining treatment options for infertility in women with endometrio-
sis. However, there are several limitations of this study such as retro-
spective design, small sample size. Therefore, large scale study should 
be performed to determine the consensual cut-off value in endome-
triosis.
In conclusion, compared with women who do not have endometri-
osis, the current study showed that the serum AMH level was signifi-
cantly lower, and the serum FSH level was significantly higher in wo-
men with endometriosis. This study indicates that serum AMH repre-
sents a useful marker of ovarian response to COH in patients with en-
dometriosis. In particular, it is useful for predicting the ovarian response 
to COH in women with a high serum FSH level. www.eCERM.org
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